Pfizer Dashes Hopes For A PCSK9 Pill
Pfizer has decided not to move forward with an oral PCSK9 blocker in early clinical development because the efficacy wouldn’t stand up to injectable rivals.
Pfizer has decided not to move forward with an oral PCSK9 blocker in early clinical development because the efficacy wouldn’t stand up to injectable rivals.